Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 1 study of subcutaneous injection strategies for COR-1167 in healthy participants
NL-OMON61122Phase 1Completed
- Sponsor
- Corteria Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of COR-1167 in chronic heart failure (CHF) (2 arms), sponsored by Corteria Pharmaceuticals. Primary endpoint: Primary endpoint(s). Started May 2026; status: completed.
02
Drugs
COR-1167
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON61122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61122.